Pathogenesis of preeclampsia

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 2, 2015, Pages 131-138

  Sircar, Monica ^a   Thadhani, Ravi ^a   Karumanchi, S Ananth ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenic factors; Placental growth factor; Preeclampsia; Pregnancy; Proteinuria; Soluble fms like tyrosine kinase 1; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PLACENTA PROTEIN;

ARTICLE; CHRONIC KIDNEY DISEASE; ENDOTHELIAL DYSFUNCTION; HEMODYNAMIC PARAMETERS; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PLACENTA DISORDER; PREECLAMPSIA; PREMATURE LABOR; PRIORITY JOURNAL; PROGNOSIS; ANIMAL; BLOOD; COMPLICATION; FEMALE; HYPERTENSION; KIDNEY DISEASES; METABOLISM; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PROTEINURIA; VASCULARIZATION;

ANIMALS; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PROTEINURIA;

EID: 84922666255     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000105     Document Type: Article

References (75)

1. Bosio PM, McKenna PJ, Conroy R, O'Herlihy C. Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol 1999; 94:978-984.
2. Thadhani R, Ecker JL, Kettyle E, et al. Pulse pressure and risk of preeclampsia: a prospective study. Obstet Gynecol 2001; 97:515-520.
3. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122:1122-1131.
4. Chen CW, Jaffe IZ, Karumanchi SA. Preeclampsia and cardiovascular disease. Cardiovasc Res 2014; 101:579-586.
5. Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet 2005; 365:785-799.
6. Duley L. The global impact of preeclampsia and eclampsia. Semin Perinatol 2009; 33:130-137.
7. Ananth CV, Keyes KM, Wapner RJ. Preeclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ 2013; 347:f6564.
8. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol 2010; 5:173-192.
9. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997; 99:2152-2164.
10. Lyall F, Robson SC, Bulmer JN. Spiral artery remodeling and trophoblast invasion in preeclampsia and fetal growth restriction: relationship to clinical outcome. Hypertension 2013; 62:1046-1054.
11. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007; 50:1142-1147.
12. Makris A, Thornton C, Thompson J, et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007; 71:977-984.
13. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science 1997; 277:1669-1672.
14. Karumanchi SA, Maynard SE, Stillman IE, et al. Preeclampsia: a renal perspective. Kidney Int 2005; 67:2101-2113.
15. Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161:1200-1204.
16. Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol 2007; 18:2281-2284.
17. Pinheiro MB, Gomes KB, Dusse LM. Fibrinolytic system in preeclampsia. Clin Chim Acta 2013; 416:67-71.
18. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004; 95:884-891.
19. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658.
20. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011; 123:2856-2869.
21. Sela S, Itin A, Natanson-Yaron S, et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 2008; 102:1566-1574.
22. Li F, Hagaman JR, Kim HS, et al. eNOS deficiency acts through endothelin to aggravate sFlt-1-induced preeclampsia-like phenotype. J Am Soc Nephrol 2012; 23:652-660.
23. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129-1136.
24. Patel TV, Morgan JA, Demetri GD, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008; 100:282-284.
25. Vigneau C, Lorcy N, Dolley-Hitz T, et al. All antivascular endothelial growth factor drugs can induce 'preeclampsia-like syndrome': a RARe study. Nephrol Dial Transplant 2014; 29:325-332.
26. Eremina V, Quaggin SE. The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 2004; 13:9-15.
27. Mattot V, Moons L, Lupu F, et al. Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J Am Soc Nephrol 2002; 13:1548-1560.
28. Garovic VD, Wagner SJ, Turner ST, et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 2007; 196:320 e1-e7.
29. Maharaj AS, Walshe TE, Saint-Geniez M, et al. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 2008; 205:491-501.
30. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12:642-649.
31. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992-1005.
32. Noori M, Donald AE, Angelakopoulou A, et al. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010; 122:478-487.
33. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and antiangiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21:9-23.
34. Parikh SM, Karumanchi SA. Putting pressure on preeclampsia. Nat Med 2008; 14:810-812.
35. Burwick RM, Easter SR, Dawood HY, et al. Complement activation and kidney injury molecule-1-associated proximal tubule injury in severe preeclampsia. Hypertension 2014; 64:833-838.
36. Hoffman MC, Rumer KK, Kramer A, et al. Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am J Reprod Immunol 2014; 71:55-60.
37. Java A, Atkinson J, Salmon J. Defective complement inhibitory function predisposes to renal disease. Annu Rev Med 2013; 64:307-324.
38. Qing X, Redecha PB, Burmeister MA, et al. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int 2011; 79:331-339.
39. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103:945-952.
40. Zhou CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonistic autoantibodies induce preeclampsia in pregnant mice. Nat Med 2008; 14:855-862.
41. Fan X, Rai A, Kambham N, et al. Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. J Clin Invest 2014; 124:4941-4952.
42. Sunderji S, Gaziano E, Wothe D, et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010; 202:e1-e7.
43. Buurma AJ, Penning ME, Prins F, et al. Preeclampsia is associated with the presence of transcriptionally active placental fragments in the maternal lung. Hypertension 2013; 62:608-613.
44. Rajakumar A, Cerdeira AS, Rana S, et al. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension 2012; 59:256-264.
45. Levine RJ, Thadhani R, Qian C, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005; 293:77-85.
46. Benton SJ, Hu Y, Xie F, et al. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol 2011; 205:469.
47. Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202:161e1-161e11.
48. Verlohren S, Herraiz I, Lapaire O, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014; 63:346-352.
49. Hagmann H, Thadhani R, Benzing T, et al. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem 2012; 58:837-845.
50. Rolfo A, Attini R, Nuzzo AM, et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 2013; 83:177-181.
51. Perni U, Sison C, Sharma V, et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012; 59:740-746.
52. Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Plasma concentrations of angiogenic/antiangiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med 2014; 27:132-144.
53. Moore AG, Young H, Keller JM, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med 2012; 25:2651-2657.
54. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125:911-919.
55. Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013; 128:2121-2131.
56. Rana S, Schnettler WT, Powe C, et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 2013; 32:189-201.
57. Gilbert JS, Verzwyvelt J, Colson D, et al. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension 2010; 55:380-385.
58. Bergmann A, Ahmad S, Cudmore M, et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 2010; 14:1857-1867.
59. Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A 2011; 108:1451-1455.
60. Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb Res 2011; 127 (Suppl 3):S72-S75.
61. Suzuki H, Ohkuchi A, Matsubara S, et al. Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension 2009; 54:1129-1135.
62. Holwerda KM, Burke SD, Faas MM, et al. Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor. J Am Soc Nephrol 2014; 25:717-725.
63. Stepan H, Faber R. Elevated sFlt1 level and preeclampsia with parvovirusinduced hydrops. N Engl J Med 2006; 354:1857-1858.
64. Llurba E, Marsal G, Sanchez O, et al. Angiogenic and antiangiogenic factors before and after resolution of maternal mirror syndrome. Ultrasound Obstet Gynecol 2012; 40:367-369.
65. Hladunewich MA, Steinberg G, Karumanchi SA, et al. Angiogenic factor abnormalities and fetal demise in a twin pregnancy. Nature reviews. Nephrology 2009; 5:658-662.
66. Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124:940-950.
67. McGuane JT, Danielson LA, Debrah JE, et al. Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension 2011; 57:1151-1160.
68. Unemori E, Sibai B, Teichman SL. Scientific rationale and design of a phase I safety study of relaxin in women with severe preeclampsia. Ann N Y Acad Sci 2009; 1160:381-384.
69. Garg AX, Nevis IF, McArthur E, et al. Gestational hypertension and preeclampsia in living kidney donors. N Engl J Med 2015; 372:124-133.
70. Vikse BE, Irgens LM, Leivestad T, et al. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008; 359:800-809.
71. Vikse BE, Irgens LM, Karumanchi SA, et al. Familial factors in the association between preeclampsia and later ESRD. Clin J Am Soc Nephrol 2012; 7:1819-1826.
72. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and metaanalysis. BMJ 2007; 335:974.
73. Ray JG, Vermeulen MJ, Schull MK, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005; 366:1797-1803.
74. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 2001; 357:2002-2006.
75. Wilson BJ, Watson MS, Prescot GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003; 326:845.